Epinephrine Injection Recalled Due to Sterility Assurance Failure
Central Admixture Pharmacy Services is recalling epinephrine injection (4 mg/250 mL) following FDA inspection findings that the product's sterility cannot be assured.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a sterile injectable medication where FDA inspection raised concerns about sterility assurance. While no illnesses or injuries have been reported, lack of sterility assurance for injectable products poses significant risk of infection if contaminated, meeting the criterion of risk-of-harm products where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 5,627 bags of epinephrine added to dextrose 5% (4 mg/250 mL) with NDC 71285-7018-1. The product is a sterile injectable medication distributed nationwide in the USA.
The recall was initiated following an FDA inspection that raised questions about whether the sterility of the product could be assured. Sterile injectable medications must maintain strict sterility standards to ensure safety.
Healthcare facilities and providers that have received affected lots should discontinue use immediately. The affected lot numbers and expiration dates are: 37-883218 (04/30/2023), 37-885235 (05/08/2023), 37-885923 (05/10/2023), 37-889050 (05/23/2023), 37-890053 and 37-890054 (05/28/2023), 37-891439 and 37-891441 (06/01/2023), 37-892500 (06/06/2023), 37-894308 (06/13/2023), 37-896125 (06/20/2023), 37-896926 (06/22/2023), and 37-900396 (07/06/2023).
The recalled product
- Product
- EPINEPHrine added to dextrose 5%, 4 mg/250 mL* (16 mcg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-7018-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Sterile Injectable
- Hazard
- sterility-assurance-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-883218
- Exp 04/30/2023
- 37-885235
- Exp 05/08/2023
- 37-885923
- Exp 05/10/2023
- 37-889050
- Exp 05/23/2023
- 37-890053
- 37-890054
- Exp 05/28/2023
- 37-891439
- 37-891441
- Exp 06/01/2023
- 37-892500
- Exp 06/06/2023
- 37-894308
- Exp 06/13/2023
- 37-896125
- Exp 06/20/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27